Rosanna Carter
Psychiatric/Mental Health · Buffalo, NYNPI 1053789305
Payments from drug & device makers
Across 466 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$904
- Teva Pharmaceuticals USA, Inc.$830
- Neurocrine Biosciences, Inc.$461
- plus $1K from 11 others
What the payments were for
- Food & beverage$8,48799%
- Education$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $1,986 |
| Vanda Pharmaceuticals Inc. | 81 | $1,639 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 104 | $1,622 |
| Otsuka America Pharmaceutical, Inc. | 32 | $904 |
| Teva Pharmaceuticals USA, Inc. | 42 | $830 |
| Neurocrine Biosciences, Inc. | 27 | $461 |
| Alkermes, Inc. | 12 | $373 |
| Indivior Inc. | 21 | $262 |
| Johnson & Johnson | 7 | $149 |
| Axsome Therapeutics, Inc. | 4 | $95 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Sunovion Pharmaceuticals Inc. | 2 | $48 |
| Braeburn Inc. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$692
- Fanapt$494
- LYBALVI$480
- VRAYLAR$469
- ABILIFY ASIMTUFII$133
- ABILIFY MAINTENA$133
- REXULTI$125
- Austedo XR$121
How this compares
$8,614 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 72 | $565,856 |
| Invega SustennaPaliperidone Palmitate | 61 | $185,608 |
| VraylarCariprazine Hcl | 89 | $145,011 |
| Austedo XrDeutetrabenazine | 18 | $120,945 |
| Abilify AsimtufiiAripiprazole | 12 | $70,832 |
| RexultiBrexpiprazole | 45 | $67,943 |
| Abilify MaintenaAripiprazole | 19 | $56,171 |
| Clozapine | 596 | $51,703 |
| CaplytaLumateperone Tosylate | 23 | $37,910 |
| Clozapine OdtClozapine | 26 | $33,710 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $27,530 |
| TrintellixVortioxetine Hydrobromide | 35 | $19,155 |
| Lurasidone Hcl | 29 | $19,067 |
| ZyprexaOlanzapine | 13 | $14,359 |
| Lisdexamfetamine Dimesylate | 33 | $10,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $461 | $565,85672 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti, Abilify Maintena | $904 | $194,94576 claims |
| Johnson & JohnsonInvega Sustenna | $149 | $185,60861 claims |
| AbbVieVraylar | $1,986 | $145,01189 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $830 | $120,94518 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,622 | $37,91023 claims |
| Alkermes, Inc.Lybalvi | $373 | $27,53017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14 | $19,15535 claims |
| Indivior Inc.Suboxone | $262 | $7,25513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Buffalo
- Carl de FrancoBuffalo$28K
- Sarah OtwellBuffalo$15K
- Tisha TanyiBuffalo$10K
- Richard ZawislakBuffalo$10K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.